Antrim Pharmaceuticals LLC v. Bio-Pharm, Inc.

Justia Dockets & Filings Seventh Circuit Illinois Northern District Antrim Pharmaceuticals LLC v. Bio-Pharm, Inc.

Antrim Pharmaceuticals LLC v. Bio-Pharm, Inc.

Plaintiff:	Antrim Pharmaceuticals LLC
Defendant:	Bio-Pharm, Inc.
Case Number:	1:2016cv00784
Filed:	January 19, 2016
Court:	US District Court for the Northern District of Illinois
Office:	Chicago Office
County:	Cook
Presiding Judge:	Matthew F. Kennelly
Nature of Suit:	Other Contract
Cause of Action:	28 U.S.C. § 1332
Jury Demanded By:	Plaintiff

Follow case documents by RSS

Available Case Documents

The following documents for this case are available for you to view or download:

Date Filed	Document Text
July 8, 2018	Filing 158 ORDER ON MOTIONS IN LIMINE, signed by the Honorable Matthew F. Kennelly on 7/8/2018. (mk)
April 19, 2018	Filing 85 MEMORANDUM OPINION AND ORDER signed by the Honorable Matthew F. Kennelly on 4/19/2018: For the reasons stated in the accompanying Memorandum Opinion and ORder, the Court denies Antrim's motion for summary judgment [dkt. no. 63]. The court gran ts Bio-Pharm's motion for summary judgment on Antrim's unjust enrichment claim (count 3 of Antrim's complaint), partially grants the motion on Antrim's breach of contract claim (count 1) to the extent the claim applies to ondansetron, and otherwise denies the motion [dkt. no. 75]. The case is set for a status hearing on April 24, 2018 at 9:30 a.m. to set a trial date and discuss the possibility of settlement. (mk)

Date Filed

Document Text

July 8, 2018

Filing 158 ORDER ON MOTIONS IN LIMINE, signed by the Honorable Matthew F. Kennelly on 7/8/2018. (mk)

April 19, 2018

Filing 85 MEMORANDUM OPINION AND ORDER signed by the Honorable Matthew F. Kennelly on 4/19/2018: For the reasons stated in the accompanying Memorandum Opinion and ORder, the Court denies Antrim's motion for summary judgment [dkt. no. 63]. The court gran ts Bio-Pharm's motion for summary judgment on Antrim's unjust enrichment claim (count 3 of Antrim's complaint), partially grants the motion on Antrim's breach of contract claim (count 1) to the extent the claim applies to ondansetron, and otherwise denies the motion [dkt. no. 75]. The case is set for a status hearing on April 24, 2018 at 9:30 a.m. to set a trial date and discuss the possibility of settlement. (mk)

Access additional case information on PACER

Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.

Access this case on the Illinois Northern District Court's Electronic Court Filings (ECF) System

Search for this case: Antrim Pharmaceuticals LLC v. Bio-Pharm, Inc.
Search News	[ Google News \| Marketwatch \| Wall Street Journal \| Financial Times \| New York Times ]
Search Web	[ Unicourt \| Legal Web \| Google \| Bing \| Yahoo \| Ask ]
Plaintiff: Antrim Pharmaceuticals LLC
Represented By:	W. Gordon Dobie
Search News	[ Google News \| Marketwatch \| Wall Street Journal \| Financial Times \| New York Times ]
Search Finance	[ Google Finance \| Yahoo Finance \| Hoovers \| SEC Edgar Filings ]
Search Web	[ Unicourt \| Justia Dockets \| Legal Web \| Google \| Bing \| Yahoo \| Ask ]
Defendant: Bio-Pharm, Inc.
Represented By:	John C. Gekas
Search News	[ Google News \| Marketwatch \| Wall Street Journal \| Financial Times \| New York Times ]
Search Finance	[ Google Finance \| Yahoo Finance \| Hoovers \| SEC Edgar Filings ]
Search Web	[ Unicourt \| Justia Dockets \| Legal Web \| Google \| Bing \| Yahoo \| Ask ]

Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.

Why Is My Information Online?